14th International PGD Conference, Chicago, 11-13 May 2015

ORGANIZING COMMITTEE

INTERNATIONAL SCIENTIFIC COMMITTEE

Joe Leigh Simpson, March of Dimes, New York, USA

Alan Handyside, London Bridge Fertil, Gynecology & Genetics Centre, London, UK

Luca Gianaroli, SISMER, Center of Reproductive Medicine, Bologna, Italy

Semra Kahraman, Istanbul Memoril Hospita, Istanbuil. Turkey

Anver Kuliev, Reproductive Genetics Institute/ PGDIS, Chicago, USA (Chairman)

Renee Martin, Calgary, Canada

Santiago Munne, Reprogenetics, West Orange, USA

Svetlana Rechitsky, Reproductive Genetics Institute, Chicago, USA

Jacques Cohen, RBM online, Cambridge, UK

Gary Harton, Illumina, USA

Dagan Wells, University of Oxford, Oxford, UK

Alan Thornhill, Illumina, UK

William Kearns, Shady Grove Center for Preimplantation Genetics, Rockvill, USA

Antony Gordon, Genesis Genetics Institute, London, UK

Rene Frydman, Hospital Necker-Enfants-Malades, Paris, France

Samir Hamamah, Biology and Reproductive Medicine Service, Monpellier, France

Darren Griffin, University of Kent, Canterbury, UK

Joyce Harper, University College London, London, UK

Nathan Treff, Reproductive Medicine Associates of New Jersey, Morristown, USA

David Cram, Monash University, Melbourne, Australia

Don Leigh, Genea, Sydney, Australia

Leaanda Wilton, Melbourne IVF, Melbourne, Australia

Cristina Magli, SISMER, Center of Reproductive Medicine, Bologna, Italy

Mireia Sandalinas, Reprogenetics Spain, Barcelona, Spain

Nicolas Zech, IVF Zentren, Bregenz, Austria

Kangpu Xu, Weill Medical College of Cornell University, New York, USA

LOCAL ORGANIZING COMMITTEE

Svetlana Rechitsky, Reproductive Genetic Innovations, Chicago, IL (Co-*Chairman*)

Oleg Verlinsky, Reproductive Genetic Innovations, Chicago, IL

Max Twishor, Reproductive Genetic Innovations, Chicago, IL

Gennady Podolsky, Vega Travel International, Chicago, IL

Call for abstracts

Authors are invited to submit scientific abstracts to be considered for presentation at the 14th Interconference on Preimplantation Genetic Diagnosis. The material submitted should be unpublish and not have been presented in any other meeting.

Abstracts submitted for oral or poster presentation will be evaluated by the Scientific Committee. Once an abstract is accepted, the Committee will decide whether it is to be presented as an oral con Poster.

Oral Presentation:

Each presentation, to be given by the author, should last no more than 12 minutes and will be followed by a 3-minute discussion period. Authors will be informed of the day and time of each oral presentation in the letter of acceptance of their abstract.

Poster Presentation:

Authors of those abstracts accepted for poster presentation will be notified of the day and time of their poster session. During the poster session, one of the authors must be available at the specified times to answer questions from attendees.

Information about the size and format of the posters will be given to authors in their letter of acceptance.

GENERAL RULES

Abstracts received after this deadline will not be considered. The name of the presenting author should be indicated using bold font type. Authors, whose abstract have been accepted, must register for the Congress. Failure to do so will result in exclusion from the Congress Programme.

All abstracts must be submitted through the Congress online abstract submission system. Abstracts cannot be submitted in paper form. Details can be found on the Congress Web site: www.pgdis.org online submission system will provide the appropriate fields required to submit abstracts.

Notification

Presenting authors will be notified regarding the acceptance and/or rejection of their submissions. (I March 1st, 2015). Instructions for oral and poster presentations will be included with this correspondence

All submitted abstracts will be sent to an International Panel of Reviewers. The reviewers' decision is to appeal. Submission of an abstract indicates acceptance of and compliance with the abstract submiscientific validity of the presentation, and that all authors have read and approved the abstract and submitting an abstract, the authors affirm that the work was conducted in accordance with current engulations in biomedical research. Failure to adhere to these standards will result in rejection of the presenting author is required to ensure that all co-authors are aware of the content of the abstract to the Secretariat.

With each submission, the presenting author will be the one who must include his/her address, teleprometers, and an e-mail address. This information will be used for correspondence regarding the recoff the abstract.

Abstracts requirements:

All abstracts must be submitted in English in a structured format which includes the following:

Title: Use a concise title that indicates the content of the abstract. The complete title should be cap abbreviations in the title.

Authors: Surnames and initials for every author must be provided (i.e. Jones, B.; Smith, J.; and Sil

include degrees or titles. An author's name appearing on more than one abstract must be identical i

Affiliations: Each author should be listed by institution, city, state/province and country. Do not includivision, laboratory, etc. In abstracts where the authors have different affiliations, please indicate for number of the corresponding affiliation.

Text: It should not exceed 400 words. Abstracts will be reproduced exactly as submitted and will not way. Abbreviations should be kept to a minimum. Use of standard abbreviations is acceptable. Place abbreviations in parentheses after the full term for the first time it appears. Linguistic accuracy is the authors. Drug products mentioned in the abstract should be identified by their non-proprietary respitalize non-proprietary names.

The key headings are as follows:

Objective: An introductory statement concisely indicating the purpose of the study. Design & Method: Brief description of the study and the methods used, including statistical evaluation Results: A summary confirming or refuting the hypothesis, supported by statistics, if appropriate. Conclusion: Based on the results as they appear in the abstract.

Key words. Up to three key words that summarize the contents of the abstracts can be entered and indexing the Abstract Book.

Abstracts stating that "results will be presented or discussed" are considered uninformative and may rejection.

Publication

Please note that all accepted abstracts will be published in a supplement to Reproductive BioMedicin determined).

Please avoid problems by checking your abstract carefully before sending it. No modifications can be

submission.

Authors who wish to withdraw their abstract should send a written request to: www.pgdis.org

Topics

Please indicate in the appropriate box the topic classification to which your abstract belongs. The Sc will attempt to respect the author's option regarding their self-assignment to a special topic, but it r change the allocation in order to achieve a well-balanced scientific program.

- 1. Diagnostic techniques (from FISH to NGS)
- 2. Biopsy Procedures
- 3. Embryo Development
- 4. PGD & Aneuploidy
- 5. Alternative methods for embryo selection
- 6. PGD & Monogenic diseases
- 7. PGD for HLA
- 8. PGD for Translocations
- 9. PGD Safety
- 10. Prenatal diagnosis
- 11. Stem Cells